Lyell Free Cash Flow vs Capital Expenditures Analysis

LYEL Stock

USD 0.61 0.03 5.17%

Lyell Immunopharma financial indicator trend analysis is infinitely more than just investigating Lyell Immunopharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lyell Immunopharma is a good investment. Please check the relationship between Lyell Immunopharma Free Cash Flow and its Capital Expenditures accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.

Free Cash Flow vs Capital Expenditures

Free Cash Flow vs Capital Expenditures Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lyell Immunopharma Free Cash Flow account and Capital Expenditures. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Lyell Immunopharma's Free Cash Flow and Capital Expenditures is -0.37. Overlapping area represents the amount of variation of Free Cash Flow that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of Lyell Immunopharma, assuming nothing else is changed. The correlation between historical values of Lyell Immunopharma's Free Cash Flow and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow of Lyell Immunopharma are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of Free Cash Flow i.e., Lyell Immunopharma's Free Cash Flow and Capital Expenditures go up and down completely randomly.

Correlation Coefficient

-0.37

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Capital Expenditures

Capital Expenditures are funds used by Lyell Immunopharma to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Lyell Immunopharma operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Most indicators from Lyell Immunopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lyell Immunopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.At this time, Lyell Immunopharma's Selling General Administrative is quite stable compared to the past year. Sales General And Administrative To Revenue is expected to rise to 486.91 this year, although Enterprise Value Over EBITDA will most likely fall to (1.69).

	2022	2023	2024	2025 (projected)
Interest Income	7.1M	23.5M	27.0M	28.3M
Net Interest Income	7.1M	23.5M	27.0M	28.3M

Interest Income Net Interest Income

Lyell Immunopharma fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital
Total Assets		0.92	1.0	0.96	0.99	-0.62	0.79	0.94	0.53	-0.7	-0.77	0.5	0.88	0.97	0.79	0.73	0.95	0.82	0.34	0.63	-0.3	0.92	0.87	0.78	-0.01	0.79
Short Long Term Debt Total	0.92		0.93	0.9	0.96	-0.84	0.89	1.0	0.8	-0.51	-0.94	0.5	0.76	0.82	0.95	0.93	0.97	0.93	0.54	0.75	-0.62	1.0	0.77	0.93	-0.35	0.88
Other Current Liab	1.0	0.93		0.97	0.99	-0.61	0.77	0.94	0.53	-0.7	-0.77	0.55	0.88	0.97	0.78	0.72	0.95	0.81	0.34	0.63	-0.29	0.92	0.85	0.77	0.01	0.76
Total Current Liabilities	0.96	0.9	0.97		0.94	-0.59	0.67	0.91	0.51	-0.6	-0.74	0.72	0.8	0.9	0.74	0.7	0.95	0.73	0.38	0.69	-0.28	0.89	0.72	0.69	0.02	0.64
Total Stockholder Equity	0.99	0.96	0.99	0.94		-0.71	0.84	0.98	0.64	-0.64	-0.84	0.48	0.85	0.94	0.86	0.81	0.97	0.88	0.39	0.68	-0.42	0.96	0.86	0.85	-0.13	0.84
Other Liab	-0.62	-0.84	-0.61	-0.59	-0.71		-0.88	-0.82	-0.95	0.08	0.96	-0.27	-0.39	-0.45	-0.94	-0.93	-0.78	-0.91	-0.68	-0.79	0.92	-0.85	-0.46	-0.88	0.77	-0.8
Net Tangible Assets	0.79	0.89	0.77	0.67	0.84	-0.88		0.88	0.79	-0.51	-0.94	0.08	0.73	0.71	0.92	0.9	0.81	0.99	0.58	0.54	-0.7	0.91	0.8	0.96	-0.52	0.96
Property Plant And Equipment Net	0.94	1.0	0.94	0.91	0.98	-0.82	0.88		0.78	-0.53	-0.92	0.5	0.78	0.85	0.94	0.91	0.97	0.92	0.49	0.74	-0.58	1.0	0.79	0.92	-0.31	0.88
Current Deferred Revenue	0.53	0.8	0.53	0.51	0.64	-0.95	0.79	0.78		0.02	-0.9	0.28	0.28	0.34	0.94	0.95	0.71	0.82	0.65	0.79	-0.95	0.81	0.36	0.87	-0.82	0.77
Net Debt	-0.7	-0.51	-0.7	-0.6	-0.64	0.08	-0.51	-0.53	0.02		0.34	-0.07	-0.94	-0.83	-0.31	-0.28	-0.48	-0.48	-0.04	0.11	-0.23	-0.51	-0.89	-0.46	-0.42	-0.56
Retained Earnings	-0.77	-0.94	-0.77	-0.74	-0.84	0.96	-0.94	-0.92	-0.9	0.34		-0.35	-0.62	-0.64	-0.96	-0.96	-0.86	-0.96	-0.62	-0.71	0.8	-0.94	-0.64	-0.95	0.6	-0.88
Accounts Payable	0.5	0.5	0.55	0.72	0.48	-0.27	0.08	0.5	0.28	-0.07	-0.35		0.23	0.4	0.33	0.33	0.59	0.19	0.14	0.65	-0.11	0.46	0.07	0.19	0.13	0.04
Cash	0.88	0.76	0.88	0.8	0.85	-0.39	0.73	0.78	0.28	-0.94	-0.62	0.23		0.94	0.59	0.56	0.73	0.73	0.26	0.21	-0.07	0.76	0.96	0.7	0.17	0.75
Non Current Assets Total	0.97	0.82	0.97	0.9	0.94	-0.45	0.71	0.85	0.34	-0.83	-0.64	0.4	0.94		0.64	0.58	0.85	0.73	0.18	0.43	-0.09	0.82	0.93	0.68	0.19	0.73
Non Currrent Assets Other	0.79	0.95	0.78	0.74	0.86	-0.94	0.92	0.94	0.94	-0.31	-0.96	0.33	0.59	0.64		0.99	0.89	0.95	0.64	0.78	-0.81	0.96	0.65	0.97	-0.61	0.91
Other Assets	0.73	0.93	0.72	0.7	0.81	-0.93	0.9	0.91	0.95	-0.28	-0.96	0.33	0.56	0.58	0.99		0.84	0.92	0.66	0.74	-0.84	0.94	0.6	0.97	-0.65	0.89
Cash And Short Term Investments	0.95	0.97	0.95	0.95	0.97	-0.78	0.81	0.97	0.71	-0.48	-0.86	0.59	0.73	0.85	0.89	0.84		0.86	0.51	0.82	-0.52	0.96	0.73	0.83	-0.24	0.78
Common Stock Total Equity	0.82	0.93	0.81	0.73	0.88	-0.91	0.99	0.92	0.82	-0.48	-0.96	0.19	0.73	0.73	0.95	0.92	0.86		0.62	0.63	-0.72	0.94	0.78	0.96	-0.52	0.94
Common Stock Shares Outstanding	0.34	0.54	0.34	0.38	0.39	-0.68	0.58	0.49	0.65	-0.04	-0.62	0.14	0.26	0.18	0.64	0.66	0.51	0.62		0.52	-0.68	0.55	0.2	0.56	-0.64	0.44
Short Term Investments	0.63	0.75	0.63	0.69	0.68	-0.79	0.54	0.74	0.79	0.11	-0.71	0.65	0.21	0.43	0.78	0.74	0.82	0.63	0.52		-0.68	0.73	0.24	0.6	-0.49	0.48
Non Current Liabilities Total	-0.3	-0.62	-0.29	-0.28	-0.42	0.92	-0.7	-0.58	-0.95	-0.23	0.8	-0.11	-0.07	-0.09	-0.81	-0.84	-0.52	-0.72	-0.68	-0.68		-0.63	-0.15	-0.74	0.95	-0.63
Capital Lease Obligations	0.92	1.0	0.92	0.89	0.96	-0.85	0.91	1.0	0.81	-0.51	-0.94	0.46	0.76	0.82	0.96	0.94	0.96	0.94	0.55	0.73	-0.63		0.78	0.94	-0.37	0.9
Other Current Assets	0.87	0.77	0.85	0.72	0.86	-0.46	0.8	0.79	0.36	-0.89	-0.64	0.07	0.96	0.93	0.65	0.6	0.73	0.78	0.2	0.24	-0.15	0.78		0.76	0.07	0.85
Other Stockholder Equity	0.78	0.93	0.77	0.69	0.85	-0.88	0.96	0.92	0.87	-0.46	-0.95	0.19	0.7	0.68	0.97	0.97	0.83	0.96	0.56	0.6	-0.74	0.94	0.76		-0.55	0.97
Total Liab	-0.01	-0.35	0.01	0.02	-0.13	0.77	-0.52	-0.31	-0.82	-0.42	0.6	0.13	0.17	0.19	-0.61	-0.65	-0.24	-0.52	-0.64	-0.49	0.95	-0.37	0.07	-0.55		-0.45
Net Invested Capital	0.79	0.88	0.76	0.64	0.84	-0.8	0.96	0.88	0.77	-0.56	-0.88	0.04	0.75	0.73	0.91	0.89	0.78	0.94	0.44	0.48	-0.63	0.9	0.85	0.97	-0.45

Click cells to compare fundamentals

Lyell Immunopharma Account Relationship Matchups

Lyell Immunopharma fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	908.3M	1.1B	937.6M	750.0M	862.5M	941.4M
Short Long Term Debt Total	54.6M	67.8M	67.7M	63.2M	72.6M	61.8M
Other Current Liab	30.2M	37.4M	28.6M	23.4M	26.9M	29.5M
Total Current Liabilities	49.3M	46.7M	37.0M	34.5M	39.7M	41.7M
Total Stockholder Equity	718.4M	929.8M	833.3M	655.0M	753.2M	779.8M
Property Plant And Equipment Net	124.1M	166.6M	166.3M	142.3M	163.7M	141.5M
Current Deferred Revenue	6.1M	5.0M	21.9M	20.4M	23.4M	12.7M
Net Debt	(85.8M)	(226.0M)	(55.9M)	(82.5M)	(94.9M)	(99.6M)
Retained Earnings	(334.1M)	(584.4M)	(767.5M)	(1.0B)	(901.9M)	(856.8M)
Accounts Payable	9.4M	3.2M	3.9M	4.8M	4.3M	3.9M
Cash	140.4M	293.8M	123.6M	145.6M	167.5M	176.0M
Non Current Assets Total	290.7M	501.1M	286.3M	195.3M	224.6M	305.5M
Non Currrent Assets Other	3.2M	3.9M	5.0M	4.5M	5.2M	4.3M
Cash And Short Term Investments	612.6M	614.8M	640.2M	546.2M	628.2M	627.0M
Short Term Investments	472.2M	321.0M	516.6M	400.6M	460.7M	450.9M
Liabilities And Stockholders Equity	908.3M	1.1B	937.6M	750.0M	862.5M	941.4M
Non Current Liabilities Total	140.6M	150.9M	67.3M	60.6M	54.5M	87.2M
Capital Lease Obligations	51.0M	67.8M	67.7M	63.2M	72.6M	60.9M
Other Current Assets	4.9M	23.0M	11.1M	8.5M	9.7M	11.4M
Other Stockholder Equity	41.4M	1.5B	1.6B	1.7B	1.9B	1.1B
Total Liab	189.8M	197.6M	104.3M	95.1M	85.6M	117.5M
Net Invested Capital	(292.5M)	929.8M	833.3M	655.0M	753.2M	443.2M
Long Term Investments	163.4M	330.5M	115.0M	48.5M	43.7M	41.5M
Property Plant And Equipment Gross	124.1M	181.2M	198.6M	194.0M	223.1M	163.1M
Total Current Assets	617.5M	626.3M	651.3M	554.7M	637.9M	635.8M
Accumulated Other Comprehensive Income	256K	(1.6M)	(7.6M)	(94K)	(84.6K)	(88.8K)
Net Working Capital	568.3M	579.5M	614.3M	520.2M	598.2M	594.1M
Short Term Debt	3.6M	1.2M	4.5M	6.3M	7.2M	7.6M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Lyell Immunopharma is a strong investment it is important to analyze Lyell Immunopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lyell Immunopharma's future performance. For an informed investment choice regarding Lyell Stock, refer to the following important reports:

How To Invest In Lyell

Details

Is Lyell Stock a good investment?

Details

What is Lyell Immunopharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.

You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.79)

Quarterly Revenue Growth

0.36

Return On Assets

(0.19)

Return On Equity

(0.33)

The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lyell Free Cash Flow vs Capital Expenditures Analysis

Free Cash Flow vs Capital Expenditures

Free Cash Flow vs Capital Expenditures Correlation Analysis

Correlation Coefficient

Free Cash Flow

Capital Expenditures

Lyell Immunopharma fundamental ratios Correlations

Lyell Immunopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lyell Immunopharma fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Current Liab	+ 1.0	Total Assets
Property Plant And Equipment Net	+ 1.0	Short Long Term Debt Total
Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Capital Lease Obligations	+ 1.0	Property Plant And Equipment Net
Total Stockholder Equity	+ 0.99	Total Assets
Total Stockholder Equity	+ 0.99	Other Current Liab

Common Stock Total Equity	- 0.96	Retained Earnings
Other Assets	- 0.96	Retained Earnings
Non Currrent Assets Other	- 0.96	Retained Earnings
Other Stockholder Equity	- 0.95	Retained Earnings
Non Current Liabilities Total	- 0.95	Current Deferred Revenue
Current Deferred Revenue	- 0.95	Other Liab